	Item No	Recommendation	Location in study
Title and abstract	1	(a) Indicate the study's design with a commonly used term	Title
		in the title or the abstract	
		(b) Provide in the abstract an informative and balanced	Abstract
		summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	Introduction (p3)
		investigation being reported	
Objectives	3	State specific objectives, including any prespecified	Introduction (p4)
		hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	Method (p4)
Setting	5	Describe the setting, locations, and relevant dates, including	Method (p4-5)
		periods of recruitment, exposure, follow-up, and data	
		collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the	Method (p4)
		sources and methods of selection of participants. Describe	
		methods of follow-up	
		Case-control study—Give the eligibility criteria, and the	
		sources and methods of case as certainment and control	
		selection. Give the rationale for the choice of cases and	
		controls	
		Cross-sectional study—Give the eligibility criteria, and the	
		sources and methods of selection of participants	
		(b) Cohort study—For matched studies, give matching	NA
		criteria and number of exposed and unexposed	
		Case-control study—For matched studies, give matching	
		criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	Method (p5)
		confounders, and effect modifiers. Give diagnostic criteria,	
		if applicable	
Data sources/	8*	For each variable of interest, give sources of data and	Method (p4)
measurement		details of methods of as sessment (measurement). Describe	
		comparability of as sessment methods if there is more than	
		one group	
Bias	9	Describe any efforts to address potential sources of bias	Method (p5) &
			Results (p6)
Study size	10	Explain how the study size was arrived at	Method (p4)
Quantitative	11	Explain how quantitative variables were handled in the	Method (p4-5) &
variables		analyses. If applicable, describe which groupings were	Results (p6)
		chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to	Method (p5)
		control for confounding	
		(b) Describe any methods used to examine subgroups and	Method (p5)

		interactions	
		(c) Explain how missing data were addressed	Table 1
		(d) Cohort study—If applicable, explain how loss to follow-	NA
		up was addressed	
		Case-control study—If applicable, explain how matching of	
		cases and controls was addressed	
		Cross-sectional study—If applicable, describe analytical	
		methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
		_ , , ,	
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	NA
<u>.</u>		numbers potentially eligible, examined for eligibility,	
		confirmed eligible, included in the study, completing follow-	
		up, and analysed	
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive	14*	(a) Give characteristics of study participants (eg	Table 1
data	17	demographic, clinical, social) and information on exposures	Table 1
uata		and potential confounders	
			Table 1
		(b) Indicate number of participants with missing data for each variable of interest	rable r
			M-411 (-4)
		(c) Cohort study—Summarise follow-up time (eg, average	Method (p4)
Outcome data	15*	and total amount) Cohort study—Report numbers of outcome events or	Table 1 + Figure 1
Outcome data	13.		Table 1 + Figure 1
		summary measures over time	NΙΛ
		Case-control study—Report numbers in each exposure	NA
		category, or summary measures of exposure	NT A
		Cross-sectional study—Report numbers of outcome events	NA
	1.0	or summary measures	D 1: (6.5)
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-	Results (p6-7)
		adjusted estimates and their precision (eg, 95% confidence	
		interval). Make clear which confounders were adjusted for	
		and why they were included	
		(b) Report category boundaries when continuous variables	Results (p4-5)
		were categorized	
		(c) If relevant, consider translating estimates of relative risk	NA
		into absoluterisk for a meaningful time period	
Otheranalyses	17	Report other analyses done—eg analyses of subgroups and	NA
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	Discussion (p8)
Limitations	19	Discuss limitations of the study, taking into account sources of	Discussion (p10)
		potential bias or imprecision. Discuss both direction and	
		magnitude of any potential bias	
Interpretation	20	C:	Discussion (ng 10)
r	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from	Discussion (p8-10)

sımılar	studies	, and other re	elevani	tevidence

Generalisability	21	Discuss the generalisability (external validity) of the study	Discussion (p10)	
		results		
Other information				
Funding	22	Give the source of funding and the role of the funders for the	P1	
		present study and, if applicable, for the original study on which		
		the present article is based		

^{*}Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist itemand gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.